Hutchmed Limited has entered into an exclusive development and license agreement with a subsidiary of GSK plc, giving the GSK subsidiary rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830.

HMPL-A830 is a first-in-class Antibody-Targeted Therapy Conjugate that combines a highly selective KRAS small-molecule inhibitor payload with an anti-EGFR antibody.

Initial clinical development will focus on colorectal, pancreatic and lung cancers. The agreement includes a $110 million upfront payment and up to $1.295 billion in potential development, regulatory and commercial milestone payments, plus royalties on net sales.

Colorectal, lung and pancreatic cancers have among the highest incidence of KRAS-altered tumors, and patients often lack safe, durable KRAS-targeted therapies. HMPL-A830 is designed to deliver a KRAS inhibitor directly to EGFR-expressing tumors while blocking EGFR and KRAS signaling to improve efficacy, durability and tolerability.

Hutchmed will lead the global phase I development program, expected to begin in the second half of 2026. GSK will handle subsequent clinical development and commercialization outside Mainland China, Hong Kong, Macau and Taiwan.

“We are proud to work with GSK, a globally leading biopharmaceutical company that, like Hutchmed, is committed to developing innovative new cancer medicines to address significant unmet medical needs worldwide,” said Johnny Cheng, Acting CEO and CFO of Hutchmed. “Our ATTCs combine antibodies with our proprietary small-molecule inhibitor payloads to deliver dual mechanisms of action. HMPL-A830 is our third drug candidate from these novel payload platforms and the first from our platform to be licensed to a global partner, following two candidates that have entered clinical development. This collaboration marks a significant step in maximizing its potential as a treatment for patients, unlocking an entirely new class of precision oncology medicines.”

Dr. Hesham Abdullah, SVP, Global Head Oncology, R&D, GSK added, “The dual KRAS-EGFR mechanism of HMPL-A830 has the potential to significantly improve upon current standard of care. We look forward to working with Hutchmed to progress this innovative asset through development.”